Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage biotech firm, reported a net loss of $26.5 million for FY 2025, up from $7.3 million in FY 2024, driven by a $20.5 million impairment loss on intangible assets related to CM24 and NT219 programs. Operating loss widened to $27.5 million from $11.0 million YoY, primarily due to this non-cash charge, despite R&D expenses dropping 53% to $3.7 million following CM24 Phase 2 completion. G&A expenses held steady at $3.2 million. No revenue was generated, consistent with pre-commercial status. Balance sheet shows $17.6 million total assets, down from $37.0 million, with cash at $8.7 million supporting operations for at least 12 months. Cash burn from operations improved to $5.7 million from $14.4 million YoY. Financing activities yielded $6.3 million, mainly from a $5.3 million net September public offering. Equity attributable to owners fell to $9.7 million. Forward-looking, focus shifts to CAPTN-3 platform (IM1240 IND in 2026), with CM24/NT219 advancement pending partnerships. Liquidity sufficient short-term, but additional funding likely needed for pipeline progression.

Key Takeaways